Results from a phase I safety lead-in study investigating the combination of erlotinib and the histone deacetylase inhibitor entinostat in patients with advanced NSCLC.

@article{Konduri2009ResultsFA,
  title={Results from a phase I safety lead-in study investigating the combination of erlotinib and the histone deacetylase inhibitor entinostat in patients with advanced NSCLC.},
  author={Katrik Konduri and Alexander I. Spira and Robert M. Jotte and Thomas E. Boyd and Yousuf Gaffar and Craig H Reynolds and Samir E. Witta},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2009},
  volume={27 15_suppl},
  pages={e14545}
}
e14545 Background: Preclinical studies showed the synergistic effect of entinostat with epidermal growth factor tyrosine kinase inhibitors (EGFR-TKI) in NSCLC cell lines. Entinostat (SNDX-275, Syndax Pharmaceuticals) is an oral, class 1 isoform selective HDACi that restores the expression of e-cadherin and sensitivity to EGFR-TKI in NSCLC cell lines. The aim of this study was to determine the safety and feasibility of combining entinostat with erlotinib in advanced NSCLC patients in order to… CONTINUE READING
2 Citations
0 References
Similar Papers

Similar Papers

Loading similar papers…